Invivyd (NASDAQ:IVVD) Given Buy Rating at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Invivyd (NASDAQ:IVVD) in a report published on Monday,Benzinga reports. The brokerage currently has a $9.00 price objective on the stock.

Several other analysts have also issued reports on the company. EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. HC Wainwright reduced their price target on Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. Finally, Morgan Stanley dropped their price objective on Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a report on Wednesday, November 20th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Invivyd has an average rating of “Buy” and a consensus price target of $7.89.

Invivyd Stock Performance

Invivyd stock opened at $1.06 on Monday. Invivyd has a twelve month low of $0.35 and a twelve month high of $5.10. The firm has a market cap of $126.80 million, a PE ratio of -0.54 and a beta of 0.61. The firm’s 50 day moving average price is $0.50 and its two-hundred day moving average price is $0.82.

Insider Activity

In other Invivyd news, Director Terrance Mcguire sold 160,400 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $0.59, for a total transaction of $94,636.00. Following the completion of the sale, the director now owns 4,202,679 shares of the company’s stock, valued at $2,479,580.61. This represents a 3.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders have sold 816,466 shares of company stock valued at $423,214. Insiders own 17.90% of the company’s stock.

Institutional Trading of Invivyd

A number of institutional investors and hedge funds have recently modified their holdings of IVVD. Proficio Capital Partners LLC bought a new position in Invivyd in the 3rd quarter worth $27,000. Barclays PLC grew its position in shares of Invivyd by 179.6% in the third quarter. Barclays PLC now owns 117,973 shares of the company’s stock valued at $120,000 after purchasing an additional 75,780 shares during the last quarter. Cubist Systematic Strategies LLC increased its stake in shares of Invivyd by 66.1% in the second quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock worth $148,000 after purchasing an additional 53,499 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Invivyd during the 2nd quarter worth about $421,000. Finally, Marshall Wace LLP boosted its stake in Invivyd by 4.2% during the 2nd quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock valued at $866,000 after purchasing an additional 31,992 shares during the period. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.